CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation Association Between Malignant Mitral Valve Prolapse and Sudden Cardiac Death: A Review The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension Thrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials Optical Coherence Tomography to Assess Proximal Side Optimization Technique in Crush Stenting Five-Year Clinical Outcomes After Drug-Eluting Stent Implantation Following Rotational Atherectomy for Heavily Calcified Lesions Orbital atherectomy for the treatment of small (2.5mm) severely calcified coronary lesions: ORBIT II sub-analysis Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis
|<<... 164 165 166 167 168 169 170 ...>>|

Guideline2019 Jan 28. pii: S1547-5271(19)30037-2.

JOURNAL：Heart Rhythm. Article Link

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

January CT, Wann LS, Calkins H et al. Keywords: acute coronary syndrome; anticoagulants; antiplatelet agents; apixaban; atrial fibrillation; atrial flutter; coronary artery disease; dabigatran; edoxaban; idarucizumab; warfarin;

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top